Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients
NCT ID: NCT00781040
Last Updated: 2019-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
273 participants
OBSERVATIONAL
2006-12-31
2019-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
NCT01535534
Inflammatory Mediators in Early Sepsis
NCT02692118
A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis
NCT07089524
Sepsis and Myocarditis
NCT07079605
Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
NCT06178822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neutropenic patients
Adult AML and ASCT patients with neutropenic fever.
Severe sepsis vs. non-severe sepsis
To compare these two groups
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Severe sepsis vs. non-severe sepsis
To compare these two groups
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age under 70 years
* neutropenic fever
Exclusion Criteria
* no neutropenic fever
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kuopio University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sari Hamalainen
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esa Jantunen, M.D, PhD
Role: STUDY_DIRECTOR
Kuopio University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kuopio University Hospital
Kuopio, , Finland
Kuopio University Hospital
Kuopio, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vanska M, Koivula I, Hamalainen S, Pulkki K, Nousiainen T, Jantunen E, Juutilainen A. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica. 2011 Sep;96(9):1385-9. doi: 10.3324/haematol.2011.044925.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH5101409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.